Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Sulkes, A.
Right arrow Articles by Schlachter, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sulkes, A.
Right arrow Articles by Schlachter, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 13:637, 2002
© 2002 European Society for Medical Oncology

Letters to the Editor

Comment on "Perhaps not everyone knows that...", (Ann Oncol 2001; 12: 1186)

A. Sulkes and J. Schlachter

Institute of Oncology, Rabin Medical Center, Petach Tikva, Israel (E-mail: asolkes@ccsg.tau.ac.il)

One of the items in your "Perhaps not everyone knows that..." section in the September 2001 issue of Annals of Oncology [1] deals with the occurrence of retinopathy in patients with malignant melanoma who receive high-dose interferon {alpha}-2b (IFN{alpha}. . . [Full Text of this Article]

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?